Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH -- Ignore unavailable to you. Want to Upgrade?

To: Craig Ferguson who wrote (628)	4/6/1998 8:32:00 AM
From: g.w. barnard	Read Replies (2) \| Respond to of 998

to all, they cancelled meeting to allow for futhur review, geez it may get ulgy today and recover later. gw News Alert from PR Newswire via Quote.com Topic: (NASDAQ:CEPH) Cephalon Inc, (NASDAQ:CHIR) Chiron Corp, Quote.com News Item #6022509 Headline: FDA Cancels Myotrophin Advisory Panel Meeting ====================================================================== WEST CHESTER, Pa., and EMERYVILLE, Calif., April 6 /PRNewswire/ -- Cephalon, Inc. (NASDAQ:CEPH) and Chiron Corporation (NASDAQ:CHIR) announced today that the U.S. Food and Drug Administration (FDA) has cancelled the Peripheral and Central Nervous System Drugs Advisory Committee meeting, scheduled for April 9, 1998, to allow the agency to continue its review of the companies' new drug application (NDA) seeking clearance to market MYOTROPHIN(R) (mecasermin) Injection for the treatment of ALS. Cephalon, Inc., headquartered in West Chester, PA, is an international biopharmaceutical company that discovers, develops and markets products to treat neurological disorders. Chiron Corporation, headquartered in Emeryville, Calif., is a leading global biotechnology company that combines diagnostic, vaccine and therapeutic strategies for controlling disease. This news release may contain forward-looking statements that involve risks and uncertainties. A full discussion of Cephalon's operations and financial condition, including factors that may affect the company's business and future prospects, is contained in documents the company files with the SEC, such as form 10-Q and 10-K reports. These documents identify important factors that could cause the company's actual performance to differ from current expectations. NOTE: Cephalon's press releases are available by fax 24 hours a day at no charge by calling PR Newswire's Company News On-Call at 800-758-5804, extension 134563. They are also posted on the Internet at prnewswire.com. SOURCE Cephalon, Inc. -0- 04/06/98 /CONTACT: Jason Rubin of Cephalon, 610-738-6302, or Jim Knighton of Chiron Corp., 510-923-6055/ /Company News On-Call: prnewswire.com or fax, 800-758-5804, ext. 134563/